US2021163602A1PendingUtilityA1

Psgl-1 modulators and uses thereof

Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTPriority: Jul 8, 2014Filed: Nov 2, 2020Published: Jun 3, 2021

Est. expiryJul 8, 2034(~7.9 yrs left)· nominal 20-yr term from priority

Y02A50/30A61P 1/04A61P 37/06C07K 16/2854A61K 48/00A61K 2039/505A61P 21/00A61P 31/18A61P 33/06A61P 35/00C07K 14/70596A61P 39/02A61P 25/00A61P 31/00A61P 9/00A61P 31/14C07K 2317/76A61P 31/20A61P 31/08A61P 31/22A61P 31/04A61P 29/00A61P 31/06A61P 37/02A61P 35/02A61P 19/02A61P 3/10A61P 33/14A61P 31/16C07K 16/2896A61P 17/06

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention relates to the seminal discovery that P-selectin glycoprotein ligand-1 (PSGL-1) modulates the immune system and immune responses. Specifically, the present invention provides PSGL-1 agonists and antagonists which increase the survival of multifunctional T cells and viral clearance. The present invention further provides methods of treating infectious diseases, cancer and immune and inflammatory diseases and disorders using a PSGL-1 modulator.

Claims

exact text as granted — not AI-modified

What is claimed is: 
     
         1 . A pharmaceutical composition comprising a P-selectin glycoprotein ligand-1 (PSGL-1) modulator, and a pharmaceutical carrier. 
     
     
         2 . The composition of  claim 1 , wherein the PSGL-1 modulator is an antibody, a small molecule, a protein, a fusion protein, or a nucleic acid. 
     
     
         3 . The composition of  claim 2 , wherein the antibody is a monoclonal antibody, chimeric antibody, human antibody, or humanized antibody.

Join the waitlist — get patent alerts

Track US2021163602A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.